[2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]carbamic acid tert-butyl ester | 1008798-51-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: [2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]carbamic acid tert-butyl ester
• CAS: 1008798-51-3
• 化学式: C₃₂H₃₆N₂O₅
• 分子量: 528.648
• InChiKey: GJWOKGXVOBSSJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.39
• 重原子数：
  39.0
• 可旋转键数：
  10.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  81.01
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  [2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以86%的产率得到6-(2-aminoethoxy)-3-{4-[(benzylethylamino)methyl]phenyl}-chromen-2-one
  参考文献：
  名称：

  Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

  摘要：

  The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD. (c) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.09.100
• 作为产物：
  描述：

  3-(4-((benzyl(ethyl)amino)methyl)phenyl)-6-hydroxy-2H-chromen-2-one 、 N-Boc-溴乙胺 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 40.0h， 以59%的产率得到[2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

  摘要：

  The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD. (c) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.09.100